Literature DB >> 3545465

Human carcinoma cell lines xenografted in athymic mice: biological and antigenic characteristics of an intraabdominal model.

M Ripamonti, S Canevari, S Ménard, D Mezzanzanica, S Miotti, R Orlandi, F Rilke, E Tagliabue, M I Colnaghi.   

Abstract

In order to investigate in vivo clinical applications of murine monoclonal antibodies directed against human ovarian carcinoma a preclinical in vivo model was developed using BALB/c athymic mice. Three human carcinoma cell lines (MCF7, HT29, and SW626) were injected into the peritoneal cavity of pristane-primed animals and the biological and antigenic characteristics of the i.p. grown tumors were studied. The animals were killed when moribund or 6-8 weeks after tumor injection. At autopsy tumor take was observed in 85% of the injected animals, whereas palpable nodules were evident in only 83%. Examination of the peritoneal cavity revealed intraabdominal carcinomatosis with tumor masses varying in size between 0.2 and 0.5 cm in diameter and tumor sheets. The most frequently affected organs were the diaphragm, the liver, and the reproductive system. Ascitic fluid formation was rare and no animal developed tumors outside the peritoneal cavity. To determine whether the in vivo tumors retained the same antigenic characteristics as the in vitro cell lines, four monoclonal antibodies (MBr1, MOv2, MOv8, and MOv15) directed against ovarian carcinoma-associated antigens and two different experimental approaches (immunofluorescence and immunoblotting) were used. Variations at either a quantitative or a qualitative level were observed for some antigens, whereas no evident changes were apparent for others. In particular, the antigens detected by MBr1 and MOv15 on the MCF7 line both maintained high levels of expression and immunoblotting staining pattern, whereas the antigens detected by MOv2 on the HT29 and SW626 lines, although present at a high level, clearly changed their staining pattern. As regards the antigens recognized by MOv8 and MOv15 on the HT29 and SW626 lines, we observed a drastic decrease in the level of their expression and in many cases a drop below the threshold of detectability of the test. The intraabdominal carcinomatosis described partially mimics the growth characteristics of human ovarian cancer and maintains the expression of some antigenic markers associated with epithelial tumors of the ovary and may therefore be useful in devising immunodiagnostic and/or immunotherapeutic strategies for ovarian carcinoma.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3545465     DOI: 10.1007/BF00199827

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  25 in total

1.  Carbohydrate epitope defined by an antitumor monoclonal antibody detected on glycoproteins and a glycolipid by immunoblotting.

Authors:  F Leoni; S Miotti; S Canevari; S Sonnino; M Ripamonti; M I Colnaghi
Journal:  Hybridoma       Date:  1986

2.  Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose.

Authors:  P L Ey; S J Prowse; C R Jenkin
Journal:  Immunochemistry       Date:  1978-07

3.  Human ovarian tumours heterotransplanted to "nude" mice.

Authors:  S Kullander; A Rausing; C Tropé
Journal:  Acta Obstet Gynecol Scand       Date:  1978       Impact factor: 3.636

4.  Production and characterization of monoclonal antibody to a 60-kD glycoprotein in ovarian carcinoma.

Authors:  M Bhattacharya; S K Chatterjee; A Gangopadhyay; J J Barlow
Journal:  Hybridoma       Date:  1985

5.  Identification of a human cancer-associated antigen defined with monoclonal antibody.

Authors:  M Bhattacharya; S K Chatterjee; J J Barlow
Journal:  Cancer Res       Date:  1984-10       Impact factor: 12.701

6.  Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.

Authors:  M J Mattes; C Cordon-Cardo; J L Lewis; L J Old; K O Lloyd
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

7.  Immunochemical analysis of the determinant recognized by a monoclonal antibody (MBr1) which specifically binds to human mammary epithelial cells.

Authors:  S Canevari; G Fossati; A Balsari; S Sonnino; M I Colnaghi
Journal:  Cancer Res       Date:  1983-03       Impact factor: 12.701

8.  Generation of monoclonal antibodies reacting with normal and cancer cells of human breast.

Authors:  S Mènard; E Tagliabue; S Canevari; G Fossati; M I Colnaghi
Journal:  Cancer Res       Date:  1983-03       Impact factor: 12.701

9.  Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice.

Authors:  T C Hamilton; R C Young; K G Louie; B C Behrens; W M McKoy; K R Grotzinger; R F Ozols
Journal:  Cancer Res       Date:  1984-11       Impact factor: 12.701

10.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.

Authors:  R C Bast; T L Klug; E St John; E Jenison; J M Niloff; H Lazarus; R S Berkowitz; T Leavitt; C T Griffiths; L Parker; V R Zurawski; R C Knapp
Journal:  N Engl J Med       Date:  1983-10-13       Impact factor: 91.245

View more
  5 in total

1.  Detection of bone marrow metastases in small cell lung cancer patients. Comparison of immunologic and morphologic methods.

Authors:  K Beiske; A T Myklebust; S Aamdal; R Langholm; E Jakobsen; O Fodstad
Journal:  Am J Pathol       Date:  1992-09       Impact factor: 4.307

2.  Immunoconjugate generation between the ribosome inactivating protein restrictocin and an anti-human breast carcinoma MAB.

Authors:  R Orlandi; S Canevari; F P Conde; F Leoni; D Mezzanzanica; M Ripamonti; M I Colnaghi
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

3.  Blocked and not blocked whole-ricin-antibody immunotoxins: intraperitoneal therapy of human tumour xenografted in nude mice.

Authors:  P Brusa; F Pietribiasi; G Bussolati; F Dosio; R Arione; P M Comoglio; M Prat; L Cattel
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Effective removal of SCLC cells from human bone marrow. Use of four monoclonal antibodies and immunomagnetic beads.

Authors:  A T Myklebust; A Pharo; O Fodstad
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

5.  Systematic analysis of T7 RNA polymerase based in vitro linear RNA amplification for use in microarray experiments.

Authors:  Jörg Schneider; Andreas Buness; Wolfgang Huber; Joachim Volz; Petra Kioschis; Mathias Hafner; Annemarie Poustka; Holger Sültmann
Journal:  BMC Genomics       Date:  2004-04-30       Impact factor: 3.969

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.